<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855955</url>
  </required_header>
  <id_info>
    <org_study_id>CTXSP0001</org_study_id>
    <nct_id>NCT04855955</nct_id>
  </id_info>
  <brief_title>Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease</brief_title>
  <official_title>Individual Patient Expanded Access Investigation New Drug (IND) Application for Administration of Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltex Therapeutics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltex Therapeutics Corporation</source>
  <brief_summary>
    <textblock>
      This is a single patient emergency expanded access clinical study to assess the safety of&#xD;
      administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject&#xD;
      will be evaluated for disease-associated severity according to symptoms, cognitive function,&#xD;
      memory, and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Alzheimer Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipose-Derived Mesenchymal Stem Cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive&#xD;
             disability.&#xD;
&#xD;
          -  All current anti-Alzheimer medicines cannot prevent disease progression and the&#xD;
             patient's mental and physical ability persistently declined&#xD;
&#xD;
          -  Patient's legal guardian and caregiver must voluntarily sign an approved written&#xD;
             consent form after ample explanation of the proposed therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of malignancy&#xD;
&#xD;
          -  Renal/liver dysfunction: Exceed two times as normal subject&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Received other trial drugs within 30 days after participation of this study&#xD;
&#xD;
          -  Experienced major surgery or trauma in the last 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Richard L Neel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Little Alsace Urgent Care Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Young, M.D., Ph.D</last_name>
    <phone>713-817-8987</phone>
    <email>jyoung@celltexbank.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sally McGahee</last_name>
    <phone>713-554-6847</phone>
    <email>smcgahee@celltexbank.com</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Adipose-derived Stem Cells (AdMSCs)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

